Fluence Lines Up 2300 Megawatt-hours of Orders for Sixth-Generation Energy Storage Technology From Customers Including Enel, LS Power, sPower and Siemens
16.6.2020 14:00:00 EEST | Business Wire | Press release
Fluence, a Siemens and AES company, today unveiled its sixth-generation energy storage technology stack combining factory-built hardware, advanced software and data-driven intelligence. Drawing on more than 12 years of industry leadership and innovation, the new technology is changing the way energy storage systems are built and operated — making them simpler, safer, faster and more cost-effective to deploy at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005326/en/
Fluence's three purpose-built energy storage systems (Photo: Fluence)
The technology stack creates the foundation for three purpose-built systems, GridstackTM, SunstackTM and EdgestackTM, that are configured for grid, renewable and commercial & industrial (C&I) applications, respectively, while easily addressing the need for larger systems and larger fleets of systems. Fluence has already been selected by leading customers such as Enel, LS Power, sPower and Siemens for 800 megawatts, 2300 megawatt-hours, of projects using the new technology.
“Energy storage applications require highly flexible systems that can be tailored to specific markets and customer needs,” said Fluence CTO Brett Galura. “Until now, customers were forced to choose between custom-built solutions or inflexible, vertically integrated products. This sixth-generation technology combines our proprietary dataset – among the industry’s largest – and our deep industry experience to deliver unparalleled intelligence and flexibility, while adding the benefits of mass production to standardize safety features and significantly reduce the time and cost needed to deploy energy storage. Over the past decade, Fluence has reduced the total cost of energy storage systems by 90 percent; our new technology stack focuses on driving down the non-battery costs of energy storage systems by up to 25 percent, while empowering gigawatt-sized deployments.”
Fluence’s new technology stack includes three components:
- Fluence IQ: Digital intelligence engines use data and machine learning to improve system decision-making, manage battery degradation, reduce operating costs and optimize energy market dispatch.
- Fluence Operating System (OS): Built on a decade of digital control system development, the fully integrated operating platform combines comprehensive controls, system visibility and asset management to improve asset performance at a single site or across entire fleets.
- Fluence Cube: The factory-assembled building block is 4-5x more modular than traditional systems and incorporates the latest technologies for rapid installation and scale, consistent operations & maintenance and improved quality control.
Fluence Cube, OS and IQ incorporate enhanced safety features to meet the most stringent safety standards, such as NFPA 855 and UL 9540A. Together, they provide the foundation for three pre-configured energy storage systems optimized for specific market segments and project needs:
- Gridstack: A utility-scale system designed for the most demanding grid applications (such as T&D enhancement, frequency regulation and capacity peak power), with industry-leading reliability and safety.
- Sunstack: A PV-optimized, co-located system designed to improve and expand the capabilities of solar generation with firm renewable energy delivery and additional grid services.
- Edgestack: A commercial & industrial system designed to support 500+ kW applications with rapid deployment and minimum footprint to reduce demand charges and provide critical power.
Major global power suppliers and industrial customers have already committed to deploy Fluence’s sixth-generation technology in Asia Pacific, North America and Europe. Siemens is delivering Gridstack and Edgestack for customers in Germany, Portugal and Finland.
“Battery storage is a rapidly growing segment and crucial for the energy transition. For the cost-efficient and fast execution of projects in the area of distributed energy, microgrids and eMobility infrastructure, the productization and modularization of storage technologies are decisive. With the new stack & OS approach, Fluence has a unique system providing cutting-edge safety,” said Jean-Christoph Heyne, Global Head of Future Grids, Siemens AG.
“Cost-competitive technologies, aggressive emissions targets and increased need for grid reliability and resilience are driving global utility and C&I demand for energy storage, which BloombergNEF predicts will attract more than $560 billion in investment by 2040,” said Fluence CEO Manuel Perez Dubuc. “What separates our carbon-intensive past from a sustainable future is market inflection. With the introduction of our next-generation design, Fluence is helping drive that inflection, making it more cost-effective, faster and safer to replace smokestacks with tech stacks that provide communities around the world with cleaner, more resilient energy systems.”
About Fluence
Fluence, a Siemens and AES company, is the global market leader in energy storage technology solutions and services, combining the agility of a technology company with the expertise, vision and financial backing of two well-established and respected industry giants. Building on the pioneering work of AES Energy Storage and Siemens energy storage, the company’s goal is to create a more sustainable future by transforming the way we power our world. Providing design, delivery and integration, Fluence offers proven energy storage technology solutions that address the diverse needs and challenges of customers in a rapidly transforming energy landscape. The company currently has more than 2.1 gigawatts of projects in operation or awarded across 22 countries and territories worldwide. Fluence topped the Navigant Research utility-scale energy storage leaderboard in 2018 and was named one of Fast Company’s Most Innovative Companies in 2019.
To learn more about Fluence, please visit: fluenceenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005326/en/
Contact information
Alison Mickey, director of communications
E: alison.mickey@fluenceenergy.com
O: 703-721-8818
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom